Mia M, Howlader M, Akter F, Hossain M
Clin Pathol. 2024; 17:2632010X241263054.
PMID: 39070952
PMC: 11282570.
DOI: 10.1177/2632010X241263054.
Biswal S, Mondal S, Mondal P
J Pharm Bioallied Sci. 2021; 13(1):69-75.
PMID: 34084050
PMC: 8142922.
DOI: 10.4103/jpbs.JPBS_337_19.
Marin R, Behl T, Negrut N, Bungau S
Biomedicines. 2021; 9(3).
PMID: 33803812
PMC: 8003312.
DOI: 10.3390/biomedicines9030313.
Singh T, Parida S, Lingaraju M, Kesavan M, Kumar D, Singh R
Pharmacol Rep. 2020; 72(6):1479-1508.
PMID: 32889701
PMC: 7474498.
DOI: 10.1007/s43440-020-00155-6.
Wick S, Walsh 3rd D, Bobrow J, Hamad-Schifferli K, Kong D, Thorsen T
ACS Synth Biol. 2019; 8(5):1010-1025.
PMID: 30920800
PMC: 6830305.
DOI: 10.1021/acssynbio.8b00450.
Darunavir Population Pharmacokinetic Model Based on HIV Outpatient Data.
Daskapan A, Tran Q, Cattaneo D, Gervasoni C, Resnati C, Stienstra Y
Ther Drug Monit. 2018; 41(1):59-65.
PMID: 30489547
PMC: 6358182.
DOI: 10.1097/FTD.0000000000000576.
Complex Drug-Drug-Gene-Disease Interactions Involving Cytochromes P450: Systematic Review of Published Case Reports and Clinical Perspectives.
Storelli F, Samer C, Reny J, Desmeules J, Daali Y
Clin Pharmacokinet. 2018; 57(10):1267-1293.
PMID: 29667038
DOI: 10.1007/s40262-018-0650-9.
Role of P-Glycoprotein Inhibitors in the Bioavailability Enhancement of Solid Dispersion of Darunavir.
Rehman S, Nabi B, Fazil M, Khan S, Bari N, Singh R
Biomed Res Int. 2017; 2017:8274927.
PMID: 29226149
PMC: 5684613.
DOI: 10.1155/2017/8274927.
Chronic Effects of Ethanol and/or Darunavir/Ritonavir on U937 Monocytic Cells: Regulation of Cytochrome P450 and Antioxidant Enzymes, Oxidative Stress, and Cytotoxicity.
Rao P, Kumar S
Alcohol Clin Exp Res. 2016; 40(1):73-82.
PMID: 26727525
PMC: 4700550.
DOI: 10.1111/acer.12938.
Pharmacokinetic interactions between BMS-626529, the active moiety of the HIV-1 attachment inhibitor prodrug BMS-663068, and ritonavir or ritonavir-boosted atazanavir in healthy subjects.
Zhu L, Hruska M, Hwang C, Shah V, Furlong M, Hanna G
Antimicrob Agents Chemother. 2015; 59(7):3816-22.
PMID: 25870057
PMC: 4468697.
DOI: 10.1128/AAC.04914-14.
Protease inhibitors effectively block cell-to-cell spread of HIV-1 between T cells.
Titanji B, Aasa-Chapman M, Pillay D, Jolly C
Retrovirology. 2013; 10:161.
PMID: 24364896
PMC: 3877983.
DOI: 10.1186/1742-4690-10-161.
Gag-Pol processing during HIV-1 virion maturation: a systems biology approach.
Konnyu B, Sadiq S, Turanyi T, Hirmondo R, Muller B, Krausslich H
PLoS Comput Biol. 2013; 9(6):e1003103.
PMID: 23754941
PMC: 3675044.
DOI: 10.1371/journal.pcbi.1003103.
Darunavir is predominantly unbound to protein in cerebrospinal fluid and concentrations exceed the wild-type HIV-1 median 90% inhibitory concentration.
Croteau D, Rossi S, Best B, Capparelli E, Ellis R, Clifford D
J Antimicrob Chemother. 2012; 68(3):684-9.
PMID: 23143899
PMC: 3566670.
DOI: 10.1093/jac/dks441.
Role of darunavir in the management of HIV infection.
Lascar R, Benn P
HIV AIDS (Auckl). 2011; 1:31-9.
PMID: 22096377
PMC: 3218677.
DOI: 10.2147/hiv.s5397.
Switch from enfuvirtide to raltegravir lowers plasma concentrations of darunavir and tipranavir: a pharmacokinetic substudy of the EASIER-ANRS 138 trial.
Goldwirt L, Braun J, de Castro N, Charreau I, Barrail-Tran A, Delaugerre C
Antimicrob Agents Chemother. 2011; 55(7):3613-5.
PMID: 21576452
PMC: 3122468.
DOI: 10.1128/AAC.01827-10.
Pharmacokinetic interactions of maraviroc with darunavir-ritonavir, etravirine, and etravirine-darunavir-ritonavir in healthy volunteers: results of two drug interaction trials.
Kakuda T, Abel S, Davis J, Hamlin J, Scholler-Gyure M, Mack R
Antimicrob Agents Chemother. 2011; 55(5):2290-6.
PMID: 21383098
PMC: 3088221.
DOI: 10.1128/AAC.01046-10.
Pharmacokinetics of multiple-dose darunavir in combination with low-dose ritonavir in individuals with mild-to-moderate hepatic impairment.
Sekar V, Spinosa-Guzman S, De Paepe E, Stevens T, Tomaka F, De Pauw M
Clin Pharmacokinet. 2010; 49(5):343-50.
PMID: 20384396
DOI: 10.2165/11530690-000000000-00000.
Darunavir: in treatment-experienced pediatric patients with HIV-1 infection.
McKeage K, Scott L
Paediatr Drugs. 2010; 12(2):123-31.
PMID: 20218748
DOI: 10.2165/11204530-000000000-00000.
Pharmacokinetic interaction between nevirapine and darunavir with low-dose ritonavir in HIV-1-infected patients.
Sekar V, Lefebvre E, Marien K, De Pauw M, Vangeneugden T, Pozniak A
Br J Clin Pharmacol. 2009; 68(1):116-9.
PMID: 19660009
PMC: 2732946.
DOI: 10.1111/j.1365-2125.2009.03430.x.
Darunavir: a review of its use in the management of HIV infection in adults.
McKeage K, Perry C, Keam S
Drugs. 2009; 69(4):477-503.
PMID: 19323590
DOI: 10.2165/00003495-200969040-00007.